Abstract
Adoptive transfer of genetically engineered T cells can lead to profound and durable responses in patients with hematologic malignancies, generating enormous enthusiasm among scientists, clinicians, patients, and biotechnology companies. The success of adoptive cellular immunotherapy depends upon the ability to manufacture good quality T cells. We discuss here the methodologies and reagents that are used to generate T cells for the preclinical study of chimeric antigen receptor T cell therapy for acute myeloid leukemia (AML).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maus MV, Grupp SA, Porter DL, June CH (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17):2625–2635
Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388–398
Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39(1):49–60
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507–1517
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra225
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517–528
Kenderian SS, Ruella M, Gill S, Kalos M (2014) Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res 74(22):6383–6389
Gill S, Maus MV, Porter DL (2016) Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev 30(3):157–167
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7(303):303ra139
Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR (2013) Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer 119(15):2720–2727
Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL et al (2014) Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123(15):2343–2354
Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE et al (2013) T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 122(18):3138–3148
Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ et al (2015) CD33 specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia 29(8):1637–1647
Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O et al (2014) Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 28(8):1596–1605
Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K et al (2013) Persistence and efficacy of second generation CAR-T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 21(11):2122–2129
Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P et al (2013) CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122(20):3461–3472
Spear P, Barber A, Rynda-Apple A, Sentman CL (2013) NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol 91(6):435–440
Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL et al (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70(22):9053–9061
Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17(8):1453–1464
Acknowledgments
This work was partly supported by grants from the University of Pennsylvania-Novartis Alliance (Carl June/Saar Gill), Leukemia Lymphoma Society (Carl June/Saar Gill), and the Predolin foundation (Saad Kenderian).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Kenderian, S.S., June, C.H., Gill, S. (2017). Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia. In: Fortina, P., Londin, E., Park, J., Kricka, L. (eds) Acute Myeloid Leukemia. Methods in Molecular Biology, vol 1633. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7142-8_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7142-8_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7140-4
Online ISBN: 978-1-4939-7142-8
eBook Packages: Springer Protocols